Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPD | P32754 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384706 | 0.89 | F10 (0.43) | NR4A2NR4A1NR4A3F10BCL2 | |
| SCHEMBL4192840 | 0.89 | NR4A2 (0.44) | NR4A2NR4A1NR4A3F10KDM4E | |
| SCHEMBL4187130 | 0.88 | BCL2 (0.47) | NR4A2NR4A1NR4A3BCL2MEN1 | |
| SCHEMBL3383238 | 0.85 | PPARG (0.49) | NR4A2 | |
| SCHEMBL3381537 | 0.77 | BCL2 (0.43) | NR4A2F10KDM4EBCL2MEN1 | |
| SCHEMBL6066388 | 0.77 | NR4A2 (0.76) | NR4A2NR4A1NR4A3F10KMT2A | |
| SCHEMBL4184977 | 0.76 | BCL2 (0.47) | NR4A2BCL2MEN1KMT2AACLY | |
| SCHEMBL4190574 | 0.76 | ADAM17 (0.45) | KDM4ESLC22A12 | |
| SCHEMBL3383701 | 0.75 | SIRT2 (0.47) | NR4A2MEN1KMT2A | |
| SCHEMBL4187136 | 0.74 | PPARG (0.47) | NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572180-B1 | USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2009-02-25 | — | — | EP | claimed |
| US-7375124-B2 | Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-20 | — | — | US | claimed |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-13 | — | — | US | claimed |
| EP-1572180-A1 | USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056355-A1 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-08 | — | — | WO | claimed |
| EP-1572180-B1 | USE OF ALPHA-PHENYLTHIOCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2009-02-25 | — | — | EP | disclosed |
| US-7375124-B2 | Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-05-20 | — | — | US | disclosed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | disclosed |
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-01-31 | — | — | US | disclosed |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | SIGMA-TAU INDUSTRE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-13 | — | — | US | disclosed |
| EP-1572180-A1 | USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056355-A1 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027098-A1 | Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to PPARalpha activation | PPARA, PPARD, PPARG | NR4A2 356/4885NR4A1 242/4885NR4A3 343/4885 |
| US-20060154979-A1 | Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity | LIPC, HMGCR, PNLIP | NR4A2 2552/4885NR4A1 2840/4885NR4A3 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.